
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
INDICATIONS FOR TREATMENT — Antiviral treatment can be considered for otherwise healthy symptomatic outpatients with suspected or confirmed...
- Timing of Remdesivir for COVID-19
- Lyumjev - A New Insulin Lispro for Diabetes
- Caplacizumab (Cablivi) for iTTP
- Sublingual Apomorphine (Kynmobi) for Parkinson's Disease
- Viltolarsen (Viltepso) for Duchenne Muscular Dystrophy
- Two New Doses of Dulaglutide (Trulicity) for Diabetes
The short-acting beta2-agonist albuterol sulfate has recently become available as a large-volume (20 mL), preservative-free concentrate (albuterol inhalation solution 0.5% – Nephron Pharmaceuticals) that can be used to prepare solutions for administration of continuous nebulized albuterol (CNA). CNA is commonly used (off-label) for acute treatment of severe asthma exacerbations in hospitalized patients, particularly children.1 ...